Continuous CD8⁺ T-Cell Priming by Dendritic Cell Cross-Presentation of Persistent Antigen following Adeno-Associated Virus-Mediated Gene Delivery

Dan Xu¹,² and Christopher M. Walker¹,³,*

Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio,¹ and Integrated Biomedical Science Graduate Program² and Department of Pediatrics,³

College of Medicine, The Ohio State University, Columbus, Ohio

Received 10 June 2011/Accepted 22 August 2011

Recombinant adeno-associated virus (rAAV) vectors establish persistent transgene expression in the skeletal muscle of mice. How dendritic cells acquire encoded antigens for CD8⁺ T-cell priming is unknown. Here we document CD8⁺ T-cell priming after lethal irradiation and bone marrow reconstitution of mice treated with an AAV vector several weeks earlier. Temporal separation of vector delivery and successful class I antigen presentation indicated that T-cell priming does not necessarily require antigen synthesis in AAV-transduced dendritic cells. An apparent cross-presentation of antigen acquired from muscle suggests that strategies to limit transgene expression in dendritic cells will not prevent unwanted CD8⁺ T-cell responses.

The delivery of recombinant adeno-associated virus (rAAV) gene therapy vectors to muscle can result in long-term expression of transgenes that encode nonself proteins. CD8⁺ T cells targeting these proteins are maintained at low frequencies in the spleens and draining lymph nodes of mice but continuously infiltrate transduced muscle, where they undergo programmed death. Stable CD8⁺ T-cell frequencies can be maintained only if those that infiltrate and die in the muscle are replaced. Little is known, however, about mechanisms of class I antigen presentation and CD8⁺ T-cell priming after persistent transgene expression is established. Vector transduction and antigen synthesis by dendritic cells is thought to be required for CD8⁺ T-cell priming. Because transduced dendritic cells have a limited life span and rAAV gene therapy vectors do not replicate or spread to new cells, this mechanism cannot satisfy an apparent requirement for ongoing antigen presentation to CD8⁺ T cells. Here we demonstrate that vector-transduced dendritic cells were not involved in CD8⁺ T-cell priming. Instead, CD8⁺ T cells were primed by dendritic cells that acquired antigen from rAAV-transduced muscle cells, suggesting that strategies to restrict transgene expression to nonprofessional antigen-presenting cells will not prevent T-cell immunity.

Evidence that dendritic cells cross-present antigen encoded by recombinant DNA or viral vaccine vectors was first obtained by examining patterns of CD8⁺ T-cell priming in mice transplanted with bone marrow that was partially mismatched at H-2 class I loci (1, 3–5). We adapted this approach to determine if dendritic cells acquire antigen from rAAV-transduced muscle to continuously prime CD8⁺ T cells. As shown in Fig. 1A, DNase-resistant particles (5 × 10¹⁰) of serotype 1 or 2 rAAV vectors that encode β-galactosidase (β-Gal) (rAAV1₂-Gal and rAAV2₂-Gal, respectively) were delivered to the quadriceps muscles of CB6F1 mice. Three weeks later, the mice were irradiated (two doses of 6 Gy separated by a 4-hour interval) and reconstituted with parental (H-2b or H-2d) bone marrow that was depleted of T lymphocytes to prevent graft-versus-host disease (Fig. 1B). Transduced myocytes of CB6F1 recipient mice express H-2b and H-2d class I molecules, but bone marrow-derived mononuclear cells, including dendritic cells, should express only parental (H-2b or H-2d) class I molecules after successful bone marrow reconstitution. Chimerism was confirmed days after the transfer of BALB/c or C57BL/6 bone marrow, when greater than 98% of mononuclear cells stained with monoclonal antibodies directed against H-2b or H-2d class I molecules, respectively (Fig. 1C, left or middle panel, respectively). Containing with both antibodies was observed after the transfer of CB6F1 bone marrow (Fig. 1C, right panel). Very importantly, β-Gal expression persisted in muscle through lethal irradiation and bone marrow reconstitution. As an example, similar levels of β-Gal protein were detected in the muscles of CB6F1 mice 21 and 63 days after vector delivery (Fig. 1D). The later time point was 42 days after reconstitution with H-2b bone marrow, so there was no substantial loss of transduced myocytes due to lethal irradiation that might facilitate the cross-presentation of antigen.

The temporal separation of rAAV vector delivery to muscle and immune system reconstitution by bone marrow transfer (Fig. 1A) was an important feature of the experimental design. The process permitted a direct test of the hypothesis that CD8⁺ T-cell priming occurs continuously in animals with persistent transgene expression and does not depend on antigen presentation by vector-transduced dendritic cells. CD8⁺ T-cell priming was assessed by a gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assay after stimulation of mononuclear cells with H-2Ld⁻ or H-2Kd⁻ restricted β-Gal epitopes. In this model, the H-2Ld epitope (β-Gal₈₇₆₋₈₈₄) consisting of residues 876 to 884 of β-Gal) was consistently more
dominant than the H-2K\textsuperscript{b} epitope (\(\beta\text{-Gal}_{9252-103}\)) (Fig. 2A), but patterns of CD8\textsuperscript{T} cell priming and class I restriction could nonetheless be mapped in CB6F1 mice reconstituted with H-2\textsuperscript{d} or H-2\textsuperscript{b} bone marrow. Our observations in mice treated with the rAAV1/\(\beta\text{-Gal}\) and rAAV2/\(\beta\text{-Gal}\) vectors were consistent with CD8\textsuperscript{T} cell priming by parental dendritic cells but not by transduced F1 cells, such as myocytes. For instance, a response was detected against the H-2L\textsuperscript{d}-restricted \(\beta\text{-Gal}\) epitope, but not the H-2K\textsuperscript{b}-restricted epitope, in F1 mice reconstituted with H-2\textsuperscript{d} bone marrow (Fig. 2A). The opposite pattern of epitope recognition was observed in animals that received the H-2\textsuperscript{b} bone marrow (Fig. 2A). Mice that received autologous (H-2\textsuperscript{bxd}) bone marrow responded to both epitopes, as expected (data not shown). It is unlikely that the absence of a response restricted by the mismatched parental class I molecule was due to the skewing of the T-cell repertoire, as the same pattern of responsiveness was observed in both recipient mouse strains after a reciprocal bone marrow transplantation. Moreover, T-cell repertoires appeared normal in chimeric mice used in studies of plasmid DNA vaccines (5).

These results indicate that CD8\textsuperscript{T} cells are primed after persistent antigen production is established with an rAAV vector, providing an explanation for how the response is maintained despite the programmed death of effector populations that infiltrate transduced muscle (14). Our failure to detect responses against both \(\beta\text{-Gal}\) epitopes in mice reconstituted with H-2\textsuperscript{d} or H-2\textsuperscript{b} bone marrow excluded the possibility that transduced F1 (H-2\textsuperscript{bxd}) myocytes presented antigen directly to
CD8+ T cells. For this reason, antigen presentation by myocytes that lack the capacity for costimulatory signaling cannot explain a defective CD8+ T-cell response that failed to eliminate transduced myocytes. CD8+ T cells were primed even when vector delivery to muscle preceded reconstitution of the immune system by 3 weeks. It is very unlikely that parental dendritic cells were transduced with vector particles introduced into muscle 3 weeks earlier. In support of this argument, capsid-specific antibodies present at high titers in serum after vector delivery declined substantially following irradiation and immune reconstitution, suggesting that capsid antigens were not available to regenerate the response (Fig. 2B, left panel). Antibodies to β-Gal were maintained before and after immune reconstitution, reflecting the persistence of antigen expression in muscle (Fig. 2B, right panel). Moreover, T-cell responses against two well-defined AAV capsid epitopes presented by H-2d were not detected in F1 mice after reconstitution with H-2b or H-2d bone marrow (Fig. 2C). Capsid-specific CD8+ T-cell responses were readily generated when an H-2d immune system was transferred to F1 mice before vector delivery (Fig. 2D and E). CD8+ T-cell responses were detected against the H-2d- but not the H-2b-restricted β-Gal (Fig. 2E, left panel) and capsid (Fig. 2E, right panel) epitopes. The opposite pattern of capsid-specific CD8+ T-cell reactivity was observed after H-2b bone marrow recon-
stitution (data not shown). These results are consistent with a requirement for dendritic cells to generate a response to particle-associated capsid proteins (11, 13).

Intramuscular delivery of rAAV1\(\beta\)-Gal and rAAV2\(\beta\)-Gal induced CD8\(^+\) T-cell responses, even though the latter vector is thought to transduce dendritic cells inefficiently (7, 13). Indeed, direct transduction of dendritic cells by rAAV vectors was not required for T-cell priming once persistent antigen expression was established in this model. The pattern of CD8\(^+\) T-cell priming in bone marrow-reconstituted F1 mice is best explained by dendritic cell cross-presentation of antigen acquired from rAAV1\(\beta\)-Gal- and rAAV2\(\beta\)-Gal-transduced myocytes. Our observations also indicate that the use of cell-type-specific promoters that permit transgene expression in myocytes, but not dendritic cells, is unlikely to prevent CD8\(^+\) T-cell priming, as was previously proposed (2). Finally, the model described here may be generally useful to identify the defects in antigen presentation that reinforce priming of an ineffective CD8\(^+\) T-cell response and may be important for successful gene therapy.

We thank Brian K. Kaspar for kindly providing us with the rAAV1\(\beta\)-Gal vector and David V. Schaffer for his collaborative efforts toward the completion of this study. We are also grateful for Melinda A. Chanley’s technical assistance with animal care.

This work was supported by U.S. Public Health Service grants R01AI60388-5 to C.M.W. and 5R01HL081527-02 to David V. Schaffer for his collaborative efforts toward the completion of this study. We are also grateful for Melinda A. Chanley’s technical assistance with animal care.

This work was supported by U.S. Public Health Service grants R01AI60388-5 to C.M.W. and 5R01HL081527-02 to David V. Schaffer and C.M.W.

REFERENCES


